Ultragenyx Pharmaceutical... (RARE)
35.69
0.71 (2.03%)
At close: Apr 17, 2025, 3:59 PM
35.69
0.00%
After-hours: Apr 17, 2025, 04:31 PM EDT
Ultragenyx Pharmaceutical Revenue Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|
| Product Revenue | 71.87M | 77.25M | 73.81M | 62.49M | 138.06M | 42.35M |
| Product Revenue Growth | -6.97% | +4.67% | +18.11% | -54.74% | +226.01% | n/a |
| Royalty Revenue | 93.01M | 62.24M | 73.22M | 46.34M | 126.95M | 55.7M |
| Royalty Revenue Growth | +49.43% | -14.99% | +57.99% | -63.49% | +127.90% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| Asia Pacific Revenue | 8.93M | 77.34M | 44.71M | 301.11M | 237.67M |
| Asia Pacific Revenue Growth | -88.45% | +72.98% | -85.15% | +26.69% | n/a |
| Emea Revenue | 80.12M | 307.15M | 281.09M | n/a | n/a |
| Emea Revenue Growth | -73.91% | +9.27% | n/a | n/a | n/a |
| Latin America Revenue | 130.71M | n/a | n/a | n/a | n/a |
| Latin America Revenue Growth | n/a | n/a | n/a | n/a | n/a |
| North America Revenue | 340.46M | n/a | n/a | n/a | n/a |
| North America Revenue Growth | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 82.5M | 80.35M | 80.6M | 78.16M | 76.83M | 74.92M | 81.4M | 76.65M | 72.85M | 69.84M | 68.14M | 67.31M | 59.43M | 53.88M | 53.41M | 53.26M | 51.04M | 42.12M | 42.25M | 47.52M | 41.88M | 41.01M | 39.81M | 38.83M | 34.48M | 31.09M | 30.72M | 31.43M | 37.72M | 23.5M | 20M | 18.68M | 19.81M | 17.18M | 14.74M | 13.21M | 11.59M | 10.23M | 7.04M | 4.14M |
| Selling, General, and Administrative Revenue Growth | +2.67% | -0.31% | +3.13% | +1.73% | +2.56% | -7.97% | +6.21% | +5.21% | +4.31% | +2.50% | +1.23% | +13.26% | +10.30% | +0.89% | +0.29% | +4.34% | +21.17% | -0.31% | -11.08% | +13.47% | +2.12% | +3.00% | +2.53% | +12.63% | +10.87% | +1.23% | -2.28% | -16.66% | +60.52% | +17.47% | +7.06% | -5.67% | +15.28% | +16.59% | +11.59% | +13.92% | +13.30% | +45.38% | +70.08% | n/a |
| Research and Development Revenue | 187.77M | 170.11M | 152.64M | 169.64M | 160.56M | 157.25M | 164.95M | 165.7M | 170.81M | 237.3M | 154.53M | 143.16M | 123.01M | 113.42M | 113.2M | 147.52M | 131.1M | 87.31M | 80.71M | 112.96M | 83.06M | 100.14M | 96.05M | 78.11M | 71.62M | 70.04M | 76.83M | 75.5M | 61.53M | 60.41M | 58.44M | 51.27M | 50.75M | 48.71M | 43.33M | 40.41M | 44.56M | 29.7M | 23.1M | 17.36M |
| Research and Development Revenue Growth | +10.38% | +11.44% | -10.02% | +5.66% | +2.11% | -4.67% | -0.45% | -2.99% | -28.02% | +53.56% | +7.95% | +16.37% | +8.46% | +0.19% | -23.26% | +12.52% | +50.15% | +8.18% | -28.55% | +36.00% | -17.06% | +4.27% | +22.97% | +9.06% | +2.25% | -8.84% | +1.76% | +22.72% | +1.85% | +3.38% | +13.98% | +1.03% | +4.18% | +12.41% | +7.22% | -9.31% | +50.03% | +28.57% | +33.06% | n/a |